MedTrace Logo

Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels

NCT01138514 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1555

Last updated 2021-10-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy and safety profiles of Perrigo Israel Pharmaceuticals, Ltd. Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel and Benzaclin® Topical Gel (Clindamycin- Benzoyl Peroxide Gel).

Conditions

  • Acne Vulgaris

Interventions

DRUG

Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)

Applied to the entire face twice daily for 10 weeks

DRUG

Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)

Applied to the entire face twice daily for 10 weeks

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Padagis LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-10-31
Completion
2010-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01138514 on ClinicalTrials.gov